TKI Plus Checkpoint Inhibitor Without Chemotherapy Shows Promise as Initial Option in Advanced NSCLC
The combination of an anti-angiogenic tyrosine kinase inhibitor (TKI) and an anti-PD-1 immunotherapy proved promising, regardless of PD-L1 expression levels, as a first-line therapy for treatment-naïve patients with advanced NSCLC […] Read more
NSCLC that harbors more than one DNA damage-response (DDR) gene alteration is more likely to respond to immunotherapy than disease that harbors one or no such mutations. So concluded investigators […] Read more
Although the initial research into adoptive T-cell therapy for solid tumors was related to tumor-infiltrating lymphocytes, there is a growing interest in the use of adoptive T-cell therapy for the […] Read more